Protagonist Therapeutics, Inc.
PTGX
Updated: 23/09/2026, 11:58:05
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
No summaries found.
- Share price
- $145.07
- Market cap
- $9.33B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Dinesh V. Patel
- Employees
- 141
- IPO date
- 11/08/2016
- Beta
- 1.794
- Last dividend
- $0.00
- Day range
- $144.58 – $147.71
- 52-week range
- $62.24 – $160.81
- 1-day performance
- 0.06%
- 1-year performance
- 133.08%
- Current drawdown (1Y)
- -9.79%
- CIK
- 0001377121
- CUSIP
- 74366E102
- ISIN
- US74366E1029
- Created
- 07/12/2025, 13:49:54
- Last update
- 23/09/2026, 11:58:05
Track Protagonist Therapeutics, Inc. with an AI analyst
See which prediction-market events move PTGX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Protagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On Goal
Seeking Alpha • STOCK • 13/06/2026, 10:46:00
Protagonist Therapeutics, Inc. (PTGX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 10/06/2026, 14:12:20
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress
Accesswire • STOCK • 01/06/2026, 09:05:00
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026
Accesswire • STOCK • 28/05/2026, 09:05:00
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Accesswire • STOCK • 28/03/2026, 11:05:00
Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here's Why
Zacks Investment Research • STOCK • 20/03/2026, 14:01:25
Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?
Zacks Investment Research • STOCK • 20/03/2026, 11:06:11
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) Receives FDA Approval for ICOTYDE™
Market Data • Market Data • 18/03/2026, 22:10:39
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Sees Promising Future with FDA Approval
Market Data • Market Data • 18/03/2026, 21:15:01
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of ICOTYDE for Moderate to Severe Plaque Psoriasis Treatment Transcript
Seeking Alpha • STOCK • 18/03/2026, 16:52:21
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
Accesswire • STOCK • 18/03/2026, 09:05:00
Protagonist Therapeutics, Inc. (PTGX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Seeking Alpha • STOCK • 12/03/2026, 15:02:17